2024-20081. Medical Devices; Gastroenterology-Urology Devices; Classification of the Hemodialyzer With Expanded Solute Removal Profile
Table 1—Hemodialyzer With Expanded Solute Removal Profile Risks and Mitigation Measures
Identified risks to health Mitigation measures Adverse tissue reaction Biocompatibility evaluation, Pyrogenicity testing, and Non-clinical performance testing. Infection or pyrogen reaction Labeling, Pyrogenicity testing, Sterilization validation, Non-clinical performance testing, and Shelf-life testing. Inadequate or incomplete treatment Non-clinical performance testing, Labeling, and Shelf-life testing. Clearance of essential blood substances or medications Non-clinical performance testing, Clinical performance testing, Labeling, and Shelf-life testing. Blood loss or blood cell destruction Non-clinical performance testing, Labeling, and Shelf-life testing. Blood leak into the dialysis fluid Non-clinical performance testing, Labeling, and Shelf-life testing. Air or particle embolism Non-clinical performance testing, Labeling, and Shelf-life testing. Fluid imbalance Non-clinical performance testing and Labeling. Acid-base imbalance Non-clinical performance testing and Labeling.
Document Information
- Effective Date:
- 9/6/2024
- Published:
- 09/06/2024
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final amendment; final order.
- Document Number:
- 2024-20081
- Dates:
- This order is effective September 6, 2024. The classification was applicable on August 28, 2020.
- Pages:
- 72715-72717 (3 pages)
- Docket Numbers:
- Docket No. FDA-2024-N-3972
- Topics:
- Medical devices
- PDF File:
- 2024-20081.pdf
- CFR: (1)
- 21 CFR 876